Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer
Assessment of PD-1 and PD-L1 expression can be predictive of immunotherapy response in lung cancer. Here the authors assess the clinical toxicity, safety and quality of non-invasive imaging of PD-1 and PD-L1 expression in 13 patients with advanced lung cancer prior to treatment with immunotherapy an...
Main Authors: | A. N. Niemeijer, D. Leung, M. C. Huisman, I. Bahce, O. S. Hoekstra, G. A. M. S. van Dongen, R. Boellaard, S. Du, W. Hayes, R. Smith, A. D. Windhorst, N. H. Hendrikse, A. Poot, D. J. Vugts, E. Thunnissen, P. Morin, D. Lipovsek, D. J. Donnelly, S. J. Bonacorsi, L. M. Velasquez, T. D. de Gruijl, E. F. Smit, A. J. de Langen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2018-11-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-018-07131-y |
Similar Items
-
The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor
by: Antonia Högnäsbacka, et al.
Published: (2022-04-01) -
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities
by: Melinda Badenhorst, et al.
Published: (2024-06-01) -
Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01) -
Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice
by: Marion Chomet, et al.
Published: (2021-06-01) -
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential
by: Jossie Rotman, et al.
Published: (2020-12-01)